Belgian pharmaceutical group UCB is to evaluate whether to continue trials in two drugs for specific indications after they failed to produce satisfactory results.
UCB said in a statement on Friday that its phase IIa study of lacosamide in migraine prophylaxis did not meet a set target for reducing the frequency of migraines.
A phase IIa study in rotigotine in fibromyalgia syndrome failed to reduce pain as much as required.
More
No comments:
Post a Comment